Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 237   

Articles published

SNY 48.09
price chart
Sanofi SA (SNY) Pipeline Deserves More Credit, Says Citi
Citigroup Inc (NYSE:C), which remains neutral on Sanofi SA (ADR) (NYSE:SNY) stock, thinks that the company's pipeline deserves more credit despite the challenges its diabetes portfolio is currently facing.
AbbVie Inc (ABBV), Celgene Corporation (CELG), Sanofi SA (ADR) (SNY ...  StockWise Daily
Sanofi SA Earns Outperform Rating from Analysts at BNP Paribas (SNY)  Mideast Time
Related articles »  
Sanofi SA (SNY), Regeneron Pharmaceuticals (REGN) Eczema Drug Gets FDA ...
Sanofi SA (ADR) (NYSE:SNY) and its US-based partner Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) jointly developed experimental drug dupilumab has been granted breakthrough therapy designation by the US Food and Drug Administration for use ...
Related articles »  
Investor Watch: Fred's, Inc. (NASDAQ:FRED), Sanofi SA (ADR) (NYSE:SNY ...
Sanofi SA (ADR) (NYSE:SNY) was initiated with outperform rating coverage from analysts at Exane BNP Paribas which is being seen as a huge positive for the stock.
Related articles »  
Sanofi (SNY) Expects $37.6 Billion Revenues From New Drugs
Sanofi SA (ADR) (NYSE:SNY), which has recently been in the limelight for the much publicized ousting of its former CEO Christopher Viehbacher, expressed confidence in its drug pipeline in a statement today.
Related articles »  
Sanofi SA (SNY) Stock On A Decline Since Ousting Of CEO Chris Viehbacher
Shares of Sanofi SA (ADR) (SNY) continue their downward journey since Chris Viehbacher was ousted from his position as CEO late October by the company's board of directors in the coup led by Chairman Serge Weinberg.
Related articles »  
Sanofi Fires CEO Following Clash With Board
Sanofi SA (ADR) (SNY) announced today that the company's board has decided to oust Chief Executive Officer Christopher Viehbacher, finally putting the rumors to rest.
Related articles »  
4 Red-Hot Healthcare Stocks: Sanofi SA (ADR) (NYSE:SNY), Salix ...
Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) made noteworthy gains on Tuesday after reporting positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with ...
Related articles »  
Buzz Stocks: Orbital Sciences Corp, Sanofi SA (ADR), and American Realty ...
Futures are little changed this morning, as investors await this afternoon's policy statement from the Federal Open Market Committee (FOMC).
Dark Clouds Hover Over Sanofi SA (ADR) (NYSE:SNY) and Twitter Inc (NYSE ...  Markets Emerging
Healthcare Stocks with Major Changes- Sanofi SA (ADR) (NYSE:SNY), Eli Lilly ...  StreetWise Report
Related articles »  
Stocks Alert �Sanofi SA (ADR) (NYSE:SNY), Delphi Automotive PLC (NYSE ...
Birmingham, West Midlands - (TechSonian) - 27NOV 2014 �Sanofi SA (ADR) (NYSE:SNY)announced recently that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion ...
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »